Legend Biotech shareholders voted at annual general meeting
Bitget2026/09/24 20:00- Legend Biotech held its annual general meeting on Sept. 24, 2026.
- Shareholders received the audited consolidated financial statements for the year ended Dec. 31, 2025.
- Ernst & Young LLP was ratified as independent auditor for the fiscal year ending Dec. 31, 2026.
- Robin Meng, Corazon D. Sanders, Li Mao, Peter Salovey were re-elected as Class III directors for three-year terms.
- Share plan amendment was adopted to add 19.1 million ordinary shares; directors and officers were authorized to implement resolutions.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The US Dollar Index fell below the 101 mark, down 0.13% intraday.
Report: US-Iran conflict disrupts OPEC+ production increase schedule, capacity review postponed to mid-November
According to media reports, the capacity review work by OPEC+ has been delayed. Originally scheduled to be completed by the end of September 2026, it has now been postponed to mid-November. This theoretically still allows OPEC+ to discuss the related results at the plenary meeting in late November. The independent capacity assessment results will directly affect the production caps approved for each member country, and some member countries have already shown significant disagreements regarding quotas, putting pressure on the alliance’s stability.
Crypto prices
More
